C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional TargetsWATERTOWN, Mass., Dec. 12, 2023 -- C4 Therapeutics, Inc. , a clinical-stage...